Germany's Fresenius issues to double equity:
This article was originally published in Clinica
Executive Summary
German dialysis company Fresenius plans to double its capital to E102.4 million ($93.4 million) by issuing 10 million new ordinary shares and 10 million non-voting preferred shares. Existing ordinary shareholders will get an extra share, while non-voting preference shareholders get one new preference share for each share held. The move is designed to make Fresenius' shares "even more attractive" to a larger circle of investors, the Bad Homburg company says.
You may also be interested in...
Scrip M&A Podcast: Which Companies Could Be Acquired Next?
The editorial team from Scrip discusses the M&A potential of various emerging biopharmas, such as Viking, Verona, Altimmune, Xenon and Crinetics.
New EU Filings
Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.
P&G Restores Volume Growth In Beauty, Grooming After Pricing Run
Procter & Gamble reports strong consumer spending in the US and Europe after a 3% increase in product pricing over the past year. Dragging on fiscal third-quarter results, sales of SK-II in China fell 30% for the January-March period, while lower incidence of cough and cold impacted Health Care performance.